LifeMD to Participate in Two Investor Conferences During March

Rhea-AI Summary

LifeMD (Nasdaq: LFMD) announced management will participate in two virtual investor conferences in March 2026.

Management will attend the Mizuho Securities Healthcare Technology Conference on March 5 with virtual one-on-one meetings, and the KeyBanc Capital Markets Healthcare Forum March 17-18 with a fireside chat and a panel on March 18.

Key Figures

Mizuho conference date: March 5, 2026 KeyBanc forum dates: March 17–18, 2026 Fireside chat time: 9:00 a.m. ET +1 more

4 metrics

Mizuho conference date March 5, 2026 Mizuho Securities Healthcare Technology Conference participation

KeyBanc forum dates March 17–18, 2026 KeyBanc Capital Markets Healthcare Forum participation

Fireside chat time 9:00 a.m. ET Virtual fireside chat on March 18

GLP-1 panel time 12:00 p.m. ET Panel on GLP-1 market at KeyBanc forum

Market Reality Check

Price: $2.91 Vol: Volume 768,861 is slightl...

normal vol

$2.91 Last Close

Volume Volume 768,861 is slightly below the 20-day average of 892,163, suggesting no unusual trading activity ahead of this conference update. normal

Technical Shares at $2.91 trade below the 200-day MA of $6.84 and about 81.63% under the 52-week high, reflecting a longer-term downtrend despite today’s bounce.

Peers on Argus

LFMD gained 8.99% while momentum scanner flagged only AMWL, which was down. Seve...

1 Down

LFMD gained 8.99% while momentum scanner flagged only AMWL, which was down. Several listed health information peers (MNDR, HCAT, SLP, SOPH, CCLD) showed positive moves, but scanner data indicates LFMD’s move is more stock-specific than a broad sector rotation.

Historical Context

5 past events · Latest: Feb 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Earnings date notice	Neutral	-6.4%	Set timing for Q4 and full-year 2025 results and conference call.
Jan 06	Credit facility	Positive	+7.9%	Closed new senior secured revolving credit facility providing up to $50M availability.
Jan 05	Strategic partnership	Positive	+12.0%	Expanded Novo Nordisk collaboration to offer FDA-approved Wegovy oral semaglutide.
Dec 26	Preferred dividend	Neutral	-12.5%	Declared quarterly cash dividend on 8.875% Series A preferred stock.
Nov 24	Awards/recognition	Positive	+3.1%	Recognized in Deloitte Technology Fast 500 and TIME’s America’s Growth Leaders.

Pattern Detected

Recent news has more often seen price gains on positive strategic updates, though some neutral or administrative items have drawn negative reactions.

Recent Company History

Over the last several months, LFMD announced an expanded Novo Nordisk collaboration on the Wegovy pill, a new revolving credit facility of up to $50 million, and industry growth recognitions, all followed by positive price reactions. A preferred dividend declaration and an earnings-date notice saw declines. Compared with those more material operational and financing milestones, this conference-participation news is a lighter, investor-relations–focused update within an ongoing growth and balance-sheet repositioning story.

Market Pulse Summary

This announcement details LFMD’s participation in March investor conferences, including a GLP-1–focu...

Analysis

This announcement details LFMD’s participation in March investor conferences, including a GLP-1–focused panel and scheduled virtual meetings with investors. It follows recent strategic moves such as a new revolving credit facility and an expanded Novo Nordisk collaboration. Investors may watch for any new disclosures or guidance emerging from these events, while keeping in mind LFMD’s position well below its 52-week high of $15.84 and its ongoing balance-sheet and growth initiatives.

Key Terms

glp-1

1 terms

glp-1 medical

"a virtual panel titled “The Outlook for the GLP-1 Market: New Injection Modalities vs. Orals”"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

AI-generated analysis. Not financial advice.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March:

• Mizuho Securities Healthcare Technology Conference 2026, March 5. Management will hold virtual one-on-one meetings with investors throughout the day.
  
• KeyBanc Capital Markets Healthcare Forum, March 17-18. Management will participate in a virtual fireside chat on Wednesday, March 18^th at 9:00 a.m. Eastern time and a virtual panel titled “The Outlook for the GLP-1 Market: New Injection Modalities vs. Orals” at 12:00 p.m. Eastern time. In addition, management will hold one-on-one virtual meetings.
  

About LifeMD, Inc.

LifeMD^® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com

Media Contact
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com

FAQ

When will LifeMD (LFMD) attend the Mizuho Securities Healthcare Technology Conference in March 2026?

LifeMD will participate at Mizuho on March 5, 2026, holding virtual one-on-one investor meetings. According to the company, management will be available for virtual one-on-ones throughout the day to meet investors.

What is LifeMD's (LFMD) schedule at the KeyBanc Capital Markets Healthcare Forum March 17-18, 2026?

LifeMD management will attend KeyBanc on March 17-18, 2026, with virtual events and meetings. According to the company, there is a fireside chat March 18 at 9:00 a.m. ET and a panel at 12:00 p.m. ET plus one-on-one virtual meetings.

What topics will LifeMD (LFMD) cover in its KeyBanc panel on March 18, 2026?

LifeMD will join a panel titled “The Outlook for the GLP-1 Market: New Injection Modalities vs. Orals” at 12:00 p.m. ET. According to the company, management will discuss GLP-1 delivery modalities and market outlook during the virtual panel.

How can investors meet LifeMD (LFMD) management during the March 2026 conferences?

Investors can schedule virtual one-on-one meetings with LifeMD management at both conferences. According to the company, management will hold one-on-one virtual meetings throughout the Mizuho day and during the KeyBanc forum.

When is LifeMD's (LFMD) fireside chat at the KeyBanc forum on March 18, 2026?

LifeMD's fireside chat is scheduled for March 18, 2026 at 9:00 a.m. Eastern time. According to the company, this event will be virtual during the KeyBanc Capital Markets Healthcare Forum.